Department of Pediatrics; Program in Molecular Medicine
Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Disease Transmission, Vertical; Drug Therapy, Combination; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lymphocyte Activation; RNA, Viral; Reverse Transcriptase Inhibitors; T-Lymphocytes, Cytotoxic; Viral Load; Virus Replication
Life Sciences | Medicine and Health Sciences
Studies of potent antiretroviral combination regimens were undertaken in young infants to evaluate the potential for long-term suppression of viral replication and to evaluate the immune consequences of such therapies. Early combination antiretroviral therapy led to a loss of plasma viremia, cultivable virus, and labile extrachromosomal replication intermediates. Despite preservation of immune function, persistent human immunodeficiency type 1 (HIV-1)-specific immune responses were not detected in most infants. The absence of detectable, persisting immune responses in most HIV-1-infected infants treated early contrasts with what is typically seen in adults who are treated early. These results are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected infants allows the long-term suppression of viral replication.
J Virol. 2000 Aug;74(15):6984-91.
Journal of virology
Luzuriaga, Katherine; McManus, Margaret M.; Catalina, Michelle D.; Mayack, Shane Renee; Sharkey, Mark E.; Stevenson, Mario; and Sullivan, John L., "Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses" (2000). Open Access Articles. 1535.